Mid-Atlantic BioTherapeutics and Accelero Biostructures Join Forces to Tackle Neurological Disorders with Innovative USP30 Inhibitors
DOYLESTOWN, PA — Mid-Atlantic BioTherapeutics (MABT) and Accelero Biostructures have entered a research collaboration aimed at developing novel USP30 inhibitors. These inhibitors target neurological disorders such as Alzheimer’s and Parkinson’s Diseases, …
Mid-Atlantic BioTherapeutics and Accelero Biostructures Join Forces to Tackle Neurological Disorders with Innovative USP30 Inhibitors Read More